Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
FitzGerald, Thomas J.Document Type
Response or CommentPublication Date
2019-02-01
Metadata
Show full item recordAbstract
Comment on: PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.PMID: 30658935 Clinical Trial.Source
Fitzgerald TJ. Optimisation of adaptive therapy for advanced Hodgkin lymphoma. Lancet Oncol. 2019 Feb;20(2):167-168. doi: 10.1016/S1470-2045(19)30005-1. Epub 2019 Jan 15. PMID: 30658934. Link to article on publisher's site
DOI
10.1016/S1470-2045(19)30005-1Permanent Link to this Item
http://hdl.handle.net/20.500.14038/47906PubMed ID
30658934Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(19)30005-1